Company intelligence / Profile preview

Kato Pharmaceuticals

Laguna Hills, California, United Stateskatoclinical.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

Lead candidate Resolvine completed a Phase 1 trial for the treatment of vitreomacular attachment. The study assessed safety and efficacy in this indication. No further clinical results are publicly available.

Therapeutic areas: Ophthalmology
Modalities: Small molecules/peptide-based therapies
Industry: Biotech

Drug pipeline

1 asset

urea liposome

Phase 2

Indications: Retinal disorders, Macular disorders

Partnerships

Ophthalmic Consultants of Boston (clinical trial collaborator/sponsor)

Beyond the preview

Go deeper on Kato Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kato Pharmaceuticals.

Explore the full profile